Cardiovascular and cerebrovascular raw materials Rosuvastatin Calcium

CAS:147098-20-2

MF:C22H30CaFN3O6S

MW:523.63

EINECS:627-028-1

Specification: 99% min Rosuvastatin Calcium powder

Sample:Rosuvastatin Calcium powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Store at -20°C

Shelf Life: 2 Years

Test Method: HPLC

Rosuvastatin Calcium powder of Usage and Synthesis.

Primary hypercholesterolemia: Common dose of rosuvastatin calcium (10mg) can significantly reduce LDLC levels in patients with primary hypercholesterolemia, with greater efficiency than atorvastatin calcium (10mg), and TC and TG levels decreased more at the end of the experiment. In addition, 5mg of rosuvastatin calcium has a better effect on reducing LDLC level than 10mg of atorvastatin calcium in the same 8-week course, and the difference is statistically significant. This suggests that the lipid lowering effect of rosuvastatin calcium is better than atorvastatin calcium. Our trial is also consistent with the results of previous studies evaluating the efficacy of statins (STELLAR, MERCURY) : Rosuvastatin calcium is more potent than other statins (atorvastatin, simvastatin, and pravastatin) in reducing LDLC, enabling more patients to achieve the recommended treatment goal.

Drug interaction of Rosuvastatin Calcium.

1. Cyclosporine: When combined with cyclosporine, the AUC of rosuvastatin was 7 times higher than the average observed in healthy volunteers (compared to those taking the same dose of cyclosporine). Combined use did not affect the plasma concentration of cyclosporin.

2. Vitamin K antagonists: As with other HTG-COA reductase inhibitors, starting or gradually increasing the dose of vitamin K antagonists (such as warfarin) may lead to an increase in INR(International Normalized ratio). Discontinuation of this product or gradual reduction of the dose of this product can lead to a decrease in INR. In this case, proper detection of INR is required.

3. The combination of gemfibenzil, fenofibrate, other Bates, and lipid-lowering doses (≥1g/ day) of niacin with HMG-CoA reductase inhibitors increases the risk of myopathy, possibly due to their ability to cause myopathy when administered alone.

4. Antacids: Simultaneous administration of this product and an antacid suspension containing aluminum hydroxide magnesium can reduce the plasma concentration of rosuvastatin by approximately 50%. This effect can be mitigated if antacids are given 2 hours after taking this product. The clinical significance of this drug interaction has not been studied.

5. Erythromycin: Combined use of this product with erythromycin resulted in a 20% decrease in AUC(0-T) and a 30% decrease in Cmax of rosuvastatin. This interaction may be due to increased gastrointestinal motility caused by erythromycin. 6. Oral contraceptives/Hormone replacement Therapy (HRT) : Using this product together with oral contraceptives increases the AUC of ethinylestradiol and nogestrel by 26% and 34%, respectively. These elevated blood concentrations should be considered when choosing the dosage of oral contraceptives. There are no pharmacokinetic data available for subjects taking HRT together, so a similar interaction cannot be ruled out. However, in clinical trials, the combination was widely used and well tolerated by patients.

Pharmacological action of Rosuvastatin Calcium.

Rosuvastatin is a selective HMG-CoA reductase inhibitor. HMG-CoA reductase inhibitors are rate-limiting enzymes that convert 3-hydroxy-3-methylglutaryl-CoA to valerate, A precursor of cholesterol. The main site of action of rosuvastatin is the liver - a targeted organ for lowering cholesterol. Rosuvastatin increased the number of receptors on the surface of liver LDL cells, promoted the absorption and catabolism of LDL, inhibited the liver synthesis of VLDL, and thus reduced the total number of VLDL and LDL particles.

Product Methods of Bulk Rosuvastatin Calcium powder.